Location Madison, Wisconsin, United States Regions Great Lakes, Midwestern US Gender Male
Investor Type
Website www.clarevia.com/john-neis-2/ LinkedIn View on LinkedIn
John joined Clarevia in May of 1985 and served as its Executive Managing Director from 2000-2021. He continues to serve as a Partner.
John has extensive experience as a director of portfolio companies, including his current directorships at Cellectar BioSciences and Delphinus Medical Technologies. He has experience in assisting companies from
inception to public markets. He joined the Board of Third Wave Technologies when they had three employees and served through the initial public offering (subsequently acquired by Hologic), and he joined the Board of TomoTherapy when they had one employee and served through their public offering, which was the fourth largest healthcare IPO in the first decade of the millennium. Other notable past directorships included NimbleGen Systems, (acquired by Roche), and Inviragen (acquired by Takeda.)
He serves on the Dean’s Advisory Board, the Advisory Board of the Weinert Applied Ventures Program in the School of Business and the Tandem Press Advisory Board in the School of Education at the University of Wisconsin–Madison.
He graduated Magna Cum Laude with a BS in finance from the University of Utah and received an MS in marketing and finance from the University of Wisconsin–Madison. He is a chartered financial analyst.
